Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5984
    -0.0022 (-0.36%)
     
  • NZD/EUR

    0.5537
    -0.0006 (-0.10%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    82.62
    +1.27 (+1.56%)
     
  • GOLD

    2,236.60
    +23.90 (+1.08%)
     
  • NASDAQ

    18,285.06
    +4.22 (+0.02%)
     
  • FTSE

    7,971.93
    +39.95 (+0.50%)
     
  • Dow Jones

    39,781.56
    +21.48 (+0.05%)
     
  • DAX

    18,507.72
    +30.63 (+0.17%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.4010
    -0.3790 (-0.42%)
     

Analysts Raised Their Recommendations on Teva Stock in October

Analysts Raised Their Recommendations on Teva Stock in October

Leerink raised its recommendation on Teva Pharmaceutical Industries from “underperform” to “market perform.” The firm also raised its target price from $16 to $24 on October 1. The stock registered a rise of ~3.6% during premarket trading on the day. Teva has strong fundamentals that have been improving recently due in part to the more stable generics pricing environment in the United States.